ACTR 001

Drug Profile

ACTR 001

Alternative Names: ACTR-001; Viral ACTR T-cells + rituximab

Latest Information Update: 19 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unum Therapeutics
  • Class Antineoplastics; Monoclonal antibodies; T lymphocyte cell therapies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors; Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma

Most Recent Events

  • 19 Aug 2016 Discontinued - Preclinical for Non-Hodgkin's lymphoma in USA (Parenteral)
  • 14 Dec 2015 Preclinical trials in Non-Hodgkin's lymphoma in USA (Parenteral)
  • 14 Dec 2015 Unum Therapeutics plans a phase I trial for Non-Hodgkin lymphoma (Second-line therapy or greater) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top